Disruption of this inhibitory complex is frequently found in SLE, consistent with abnormalities related to C1q or a lack of LAIR1 and CD33 expression on circulating SLE myelomonocytes observed in SLE patients [42,43]. Here, CD33 is linked to systemic lupus erythematosus.